Studies of patients ≥80 years with PD-L1-high NSCLC show similar objective response rates and PFS to younger patients, though OS may be shorter due to lower use of subsequent therapy and increased comorbidities [55,56,57]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.